SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Big Pharma Plans Massive Ad Blitz to Fight Criticism of Drug Prices
'The idea that they are going to bring in more resources, borders on petrifying'
Aug 04, 2016
The pharmaceutical lobby is gearing up for a massive, multi-million-dollar post-election ad blitz to fight the shifting rhetoric surrounding drug prices, Politico reports.
Skyrocketing drug prices have become a central issue in the 2016 election cycle, bolstered by recent bipartisan legislation that aims to wrangle back control of the market and outspoken criticism from Bernie Sanders and Democratic nominee Hillary Clinton.
Now, the Pharmaceutical Research and Manufacturers of America (PhRMA) is planning to spend hundreds of millions of dollars to push back on politicians from both sides of the aisle--a campaign that "will dwarf the $20 million that health insurers spent on the iconic 'Harry and Louise' campaign credited with sinking...Clinton's health reform plan in the early 1990s," reports Politico's Sarah Karlin-Smith.
Karlin-Smith writes:
The group's playbook for 2017 includes adding new members, raising dues and retooling a lobbying machine that insiders say atrophied since PhRMA achieved many of its top goals with Obamacare's passage. Now it's ready to shout its message not just inside the corridors of power but beyond the Beltway.
[....] PhRMA is also meeting with political and industry insiders who will shape policy on drug prices. In July, the PhRMA board met with Clinton health policy adviser Chris Jennings, Anthem CEO Joe Swedish, Republican health economist Gail Wilensky and Steve Pearson of ICER, a research organization that analyzes the cost-effectiveness of drugs.
"They are formidable under any scenario. They are formidable now," Jennings told Politico. "The idea that they are going to bring in more resources, borders on petrifying."
But opponents say the campaign, which is expected to include commercials with "positive tones," featuring cancer survivors and soothing music, could backfire.
Topher Spiro, vice president of health policy at the Center for American Progress, told Karlin-Smith that drug lobbyists "talk a good game.... But when push comes to shove, they are not willing to budge on their public positions or their policy positions, so it's hard to give them any credit whatsoever."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
bernie sandersbig pharmacenter for american progresscorporate powerelection 2016healthcarehillary clinton
The pharmaceutical lobby is gearing up for a massive, multi-million-dollar post-election ad blitz to fight the shifting rhetoric surrounding drug prices, Politico reports.
Skyrocketing drug prices have become a central issue in the 2016 election cycle, bolstered by recent bipartisan legislation that aims to wrangle back control of the market and outspoken criticism from Bernie Sanders and Democratic nominee Hillary Clinton.
Now, the Pharmaceutical Research and Manufacturers of America (PhRMA) is planning to spend hundreds of millions of dollars to push back on politicians from both sides of the aisle--a campaign that "will dwarf the $20 million that health insurers spent on the iconic 'Harry and Louise' campaign credited with sinking...Clinton's health reform plan in the early 1990s," reports Politico's Sarah Karlin-Smith.
Karlin-Smith writes:
The group's playbook for 2017 includes adding new members, raising dues and retooling a lobbying machine that insiders say atrophied since PhRMA achieved many of its top goals with Obamacare's passage. Now it's ready to shout its message not just inside the corridors of power but beyond the Beltway.
[....] PhRMA is also meeting with political and industry insiders who will shape policy on drug prices. In July, the PhRMA board met with Clinton health policy adviser Chris Jennings, Anthem CEO Joe Swedish, Republican health economist Gail Wilensky and Steve Pearson of ICER, a research organization that analyzes the cost-effectiveness of drugs.
"They are formidable under any scenario. They are formidable now," Jennings told Politico. "The idea that they are going to bring in more resources, borders on petrifying."
But opponents say the campaign, which is expected to include commercials with "positive tones," featuring cancer survivors and soothing music, could backfire.
Topher Spiro, vice president of health policy at the Center for American Progress, told Karlin-Smith that drug lobbyists "talk a good game.... But when push comes to shove, they are not willing to budge on their public positions or their policy positions, so it's hard to give them any credit whatsoever."
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
The pharmaceutical lobby is gearing up for a massive, multi-million-dollar post-election ad blitz to fight the shifting rhetoric surrounding drug prices, Politico reports.
Skyrocketing drug prices have become a central issue in the 2016 election cycle, bolstered by recent bipartisan legislation that aims to wrangle back control of the market and outspoken criticism from Bernie Sanders and Democratic nominee Hillary Clinton.
Now, the Pharmaceutical Research and Manufacturers of America (PhRMA) is planning to spend hundreds of millions of dollars to push back on politicians from both sides of the aisle--a campaign that "will dwarf the $20 million that health insurers spent on the iconic 'Harry and Louise' campaign credited with sinking...Clinton's health reform plan in the early 1990s," reports Politico's Sarah Karlin-Smith.
Karlin-Smith writes:
The group's playbook for 2017 includes adding new members, raising dues and retooling a lobbying machine that insiders say atrophied since PhRMA achieved many of its top goals with Obamacare's passage. Now it's ready to shout its message not just inside the corridors of power but beyond the Beltway.
[....] PhRMA is also meeting with political and industry insiders who will shape policy on drug prices. In July, the PhRMA board met with Clinton health policy adviser Chris Jennings, Anthem CEO Joe Swedish, Republican health economist Gail Wilensky and Steve Pearson of ICER, a research organization that analyzes the cost-effectiveness of drugs.
"They are formidable under any scenario. They are formidable now," Jennings told Politico. "The idea that they are going to bring in more resources, borders on petrifying."
But opponents say the campaign, which is expected to include commercials with "positive tones," featuring cancer survivors and soothing music, could backfire.
Topher Spiro, vice president of health policy at the Center for American Progress, told Karlin-Smith that drug lobbyists "talk a good game.... But when push comes to shove, they are not willing to budge on their public positions or their policy positions, so it's hard to give them any credit whatsoever."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.